Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

In February 2025, the board of directors authorized a new share repurchase program to repurchase up to an additional $3.0 billion of the common stock. During the first ... under the brand name ...

Regeneron stock edged higher Thursday despite mixed results for its bread-and-butter eye-disease treatment franchise, Eylea. Please watch the video at Investors.com - How To Buy Stocks ...

comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Regeneron performed in the just reported ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

With an impressive ROA of 2.15%, the company demonstrates effective utilization of assets and strong financial performance. Debt Management: Regeneron ... and rate each stock once per quarter.

Wall Street analysts expect Regeneron (REGN ... trends in earnings estimate revision and the short-term price performance of a stock. While investors typically use consensus earnings and revenue ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall ...

Following the announcement, Regeneron’s stock price fell by 8.19% in pre-market trading, reflecting investor disappointment. This performance aligns with recent analyst sentiment, as ...

Regeneron's performance in the first quarter was dismal ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer ...